Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Response by Mackman et al to Letter Regarding Article, “Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality—Brief Report”

Response by Mackman et al to Letter Regarding Article, “Patients With COVID-19 Have Elevated... Arteriosclerosis, Thrombosis, and Vascular Biology LETTER TO THE EDITOR Response by Mackman et al to Letter Regarding Article, “Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality—Brief Report” Nigel Mackman , Yohei Hisada, Steven P. Grover , Axel Rosell , Sebastian Havervall, Fien von Meijenfeldt , Katherina Aguilera, Ton Lisman , Charlotte Thålin In Response: F. Dignat-George, personnel communication). We agree We would like to thank Brambilla et al for their inter- with Brambilla et al that there have been several sporadic est in our article showing that patients with coronavirus reports of TF protein-positive EVs in plasma samples from disease 2019 (COVID-19) have elevated levels of EVTF clinical samples by difference groups. However, none of (extracellular vesicle tissue factor) activity and that EVTF these studies present positive and negative controls, and activity is prognostic for mortality. they often use commercial anti-TF antibodies that may or 10,11 A prognostic marker is defined as a marker that is may not recognize TF. Therefore, it remains unclear associated with outcome of a disease. EVTF activity fits what is being measured in these studies. this definition without a need to define http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Arteriosclerosis Thrombosis and Vascular Biology Wolters Kluwer Health

Response by Mackman et al to Letter Regarding Article, “Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality—Brief Report”

Loading next page...
 
/lp/wolters-kluwer-health/response-by-mackman-et-al-to-letter-regarding-article-patients-with-0qeYadwJS0

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
© 2021 American Heart Association, Inc.
ISSN
1079-5642
eISSN
1524-4636
DOI
10.1161/atvbaha.121.316203
Publisher site
See Article on Publisher Site

Abstract

Arteriosclerosis, Thrombosis, and Vascular Biology LETTER TO THE EDITOR Response by Mackman et al to Letter Regarding Article, “Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality—Brief Report” Nigel Mackman , Yohei Hisada, Steven P. Grover , Axel Rosell , Sebastian Havervall, Fien von Meijenfeldt , Katherina Aguilera, Ton Lisman , Charlotte Thålin In Response: F. Dignat-George, personnel communication). We agree We would like to thank Brambilla et al for their inter- with Brambilla et al that there have been several sporadic est in our article showing that patients with coronavirus reports of TF protein-positive EVs in plasma samples from disease 2019 (COVID-19) have elevated levels of EVTF clinical samples by difference groups. However, none of (extracellular vesicle tissue factor) activity and that EVTF these studies present positive and negative controls, and activity is prognostic for mortality. they often use commercial anti-TF antibodies that may or 10,11 A prognostic marker is defined as a marker that is may not recognize TF. Therefore, it remains unclear associated with outcome of a disease. EVTF activity fits what is being measured in these studies. this definition without a need to define

Journal

Arteriosclerosis Thrombosis and Vascular BiologyWolters Kluwer Health

Published: Jun 27, 2021

References